Literature DB >> 2295857

Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.

P Kotilainen1, J Nikoskelainen, P Huovinen.   

Abstract

Seven septicemias in neutropenic leukemia patients (two with fatal outcome) caused by ciprofloxacin-resistant coagulase-negative staphylococci were diagnosed in the hematologic unit of Turku University Central Hospital in 1988 soon after the introduction of the drug. Coagulase-negative staphylococcal skin flora of 28 neutropenic patients receiving ciprofloxacin prophylaxis and therapy for gram-negative bacterial infections were compared with those of 31 untreated patients and 33 hospital personnel working in the same unit. In ciprofloxacin-treated patients the flora were almost completely ciprofloxacin-resistant, whereas in the control groups resistant flora were detected only occasionally. Similarities in the plasmid profile patterns were found in 91% of the ciprofloxacin-resistant coagulase-negative staphylococci, suggesting an epidemiologic relation between these strains. It seems evident that cross-infection is responsible for the spread of ciprofloxacin-resistant coagulase-negative staphylococci in these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295857     DOI: 10.1093/infdis/161.1.41

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates.

Authors:  P Huovinen; J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

2.  Molecular relatedness of Staphylococcus epidermidis isolates obtained during a platelet transfusion-associated episode of sepsis.

Authors:  M Shayegani; L M Parsons; A L Waring; J Donhowe; R Goering; W A Archinal; J Linden
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

3.  Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period.

Authors:  O Lyytikäinen; M Vaara; E Järviluoma; K Rosenqvist; L Tiittanen; V Valtonen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-02       Impact factor: 3.267

4.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

5.  Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.

Authors:  R Dworkin; G Modin; S Kunz; R Rich; O Zak; M Sande
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  Study of Stomatococcus mucilaginosus isolated in a hospital ward using phenotypic characterization.

Authors:  F H van Tiel; B F Slangen; H C Schouten; J A Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

8.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Use of gas-liquid chromatography for subgrouping coagulase-negative staphylococci during a nosocomial sepsis outbreak.

Authors:  P Kotilainen; P Huovinen; E Eerola
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

Review 10.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.